Shulgin, B., Kosinsky, Y., Omelchenko, A., Chu, L., Mugundu, G., Aksenov, S., Pimentel, R., DeYulia, G., Kim, G., Peskov, K., & Helmlinger, G. (2020). Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncoimmunology, 9(1), 1748982. https://doi.org/10.1080/2162402X.2020.1748982
Study results showed that unlike with PD-1 inhibitor monotherapy, CTLA-4 inhibitor monotherapy exhibited a dose/exposure dependence on most AE types evaluated. Furthermore, combination therapy with PD-1 inhibitor significantly strengthened the dependence of trAE and imAE rates on CTLA-4 inhibitor dose/exposure.
